Gene therapy using adenoviral vectors
References (0)
Cited by (112)
Innovative recombinant protein-based vaccines against SARS-CoV-2
2022, Biomedical Innovations to Combat COVID-19Biological delivery approaches for gene therapy: Strategies to potentiate efficacy and enhance specificity
2013, Molecular ImmunologyCitation Excerpt :The Ad vectors with deleted E1, with or without E3 deletion, are designated as first generation vectors. Deletion of E1 led to replication deficient viral vectors that were propagated in helper cell lines (Trapnell and Gorziglia, 1994). The first generation Ad vectors carried ∼8 kb foreign genes.
Liver-specific protein-tyrosine phosphatase 1B (PTP1B) re-expression alters glucose homeostasis of PTP1B-/- mice
2005, Journal of Biological ChemistryAdenovirus encoding soluble tumor necrosis factor α receptor immunoglobulin prolongs gene expression of a cotransfected reporter gene in rat lung
2003, Journal of Thoracic and Cardiovascular SurgeryInhibiting AIDS in the central nervous system: Gene delivery to protect neurons from HIV
2003, Molecular TherapyCitation Excerpt :For many of these diseases, transduction of terminally differentiated neurons is necessary. Poor transduction efficiencies, waning transgene expression, immune responses directed against transduced cells, and inability to retreat following an initial administration have often limited CNS-directed gene delivery [1–6]. Postmitotic neurons cannot be transduced by oncoretroviral vectors, which require that the nuclear membrane be absent to insert a transgene into the host cell genome [7].
Induction of short interspersed nuclear repeat-containing transcripts in epithelial cells upon infection with a chicken adenovirus
2003, Journal of Molecular Biology